[{"id":"5f7d029f-2d49-48f5-8f1d-6627758f9ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030066","created_at":"2021-01-18T14:54:51.381Z","updated_at":"2024-07-02T16:35:14.468Z","phase":"","brief_title":"Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas","source_id_and_acronym":"NCT03030066","lead_sponsor":"Daiichi Sankyo","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e safusidenib (DS-1001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-15"},{"id":"21c04633-ac98-4b84-8273-5cf93fa9bd61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05814536","created_at":"2023-04-18T15:04:15.128Z","updated_at":"2024-07-02T16:35:26.189Z","phase":"Phase 1","brief_title":"IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor","source_id_and_acronym":"NCT05814536","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e safusidenib (DS-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 05/06/2023","start_date":" 05/06/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-12-14"},{"id":"0156cb5f-f729-4125-aca2-e03c5032a32f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04458272","created_at":"2021-01-18T21:26:21.316Z","updated_at":"2024-07-02T16:35:26.600Z","phase":"Phase 2","brief_title":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","source_id_and_acronym":"NCT04458272","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e safusidenib (DS-1001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-12-11"},{"id":"4332101d-7ce0-4281-baf4-5b9d31806fda","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303519","created_at":"2022-03-31T17:52:38.349Z","updated_at":"2024-07-02T16:35:29.269Z","phase":"Phase 2","brief_title":"Safusidenib Phase 2 Study in IDH1 Mutant Glioma","source_id_and_acronym":"NCT05303519","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668 • safusidenib (DS-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-11-14"}]